The SOLOIST-WHF49 trial investigated combined SGLT2 and SGLT1 inhibition via sotagliflozin in recently worsening HFpEF with T2DM, although the trial was terminated early following the COVID-19 pandemic and insufficient funding. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.